Poster Session—Hepatitis (Diagnosis/Pathogenesis/Therapy)

Background Hepatitis B is a major public health problem in Vietnam. However, estimates of the prevalence of hepatitis B virus (HBV) and hepatitis Delta virus (HDV), and risk factors in rural Vietnam are limited. Methods A cross-sectional seroprevalence study was undertaken in two rural districts in Thai Binh province. The study population was randomly selected using multi-stage sampling. Demographic and behavioral risk information and serological samples were obtained from 837 participants. Results Mean age was 42.3 years ± 15.8 (range, 16–82 years) and 50.8% were female. Prevalence of HBcAb and HBsAg was 68.2% and 19.0%, respectively, and eAg was detected in 16.4% of the HBsAg positive group. Prevalence of HDV was 1.3% in the HBsAg positive group. Factors associated with HBV infection (HBcAb or HBsAg positive) were age sixty years or older (OR 3.82, 1.35–10.80; p = 0.01), residence in Vu Thu district (OR 3.00, 2.16–4.17; p < 0.0001), hospital admission (OR 2.34, 1.33–4.13; p = 0.003) and history of acupuncture (OR 2.01, 1.29–3.13; p = 0.002). Household contact with a person with liver disease (OR 2.13, 1.29–3.52; p = 0.003), reuse of syringes (OR 1.81, 1.25–2.62; p = 0.002) and sharing of razors (OR 1.69, 1.03–2.79; p = 0.04) were independent predictors of HBsAg positivity. Alanine aminotransferase (ALT) level was elevated (>40U/L) in 43% of the HBsAg positive group. Conclusion HBV infection and HBV related liver disease remains a serious public health problem in rural Vietnam. Poor infection control activities in health care settings partly accounted for the high HBV prevalence in this region. Universal HBV infant vaccination and improved infection control procedures are required for improved HBV control in Vietnam. #077 Dose-response relation of interferon-alpha in patients with HBeAg positive chronic hepatitis B: meta-analysis and meta-regression of randomized trials XIN SUN, WENXIA QIN, RONGLE ZHOU, YOUPING LI Chinese Evidence-Based Medicine Center,West China Hospital, Sichuan University, Department of Clinical Pharmacy,West School of Pharmcy, Sichuan University, West China Medical School, Sichuan University This study examined dose-response effect of interferon-α in HBeAgpositive CHB patients. We searched 5 electronic databases, all updated to September 2005. Randomized trials of interferon-α vs. non-antivirals were eligible. Quality of trials was assessed by standard instrument. Meta-regression and meta-analysis were used to examine the dose-response relation. Thirty-three trials were included (n = 2164). Dose of interferon-α ranged from 1–10 MU, and duration from 4–24 weeks. Eighteen trials were medium-to-high in quality. HBeAg clearance was responsive to dose (coef = 0.156, 95%CI = 0.028–0.28) and duration (coef = 0.076, 95%CI = 0.0048–0.15), but not for HBV-DNA clearance. Stratified analyses showed that ≥5 MU and 16–24 week interferon-α could effectively clear HBeAg (OR = 3.28, 95%CI = 2.31–4.66; OR = 3.28, 95%CI = 2.16–5.00), and HBV-DNA (OR = 2.80, 95%CI = 2.03–3.86; OR = 2.58, 95%CI = 1.62–4.12). HBeAg seroconversion could be seen in all-dose groups (OR = 2.02, 95%CI = 1.37–2.97). In conclusion, HBeAg clearance dose-responsive. A ≥5 MU and 16–24 week interferon-α could effectively clear virological and serological markers. 0 0.5 1 1.5 2 2.5 Day O D in 4 50 n m 10 microgram HCV core pcDNA3+PBS 25 microgram HCV core pcDNA3+PBS 50 microgram HCV core pcDNA3+PBS 10 microgram HCV core pcDNA3+CpG motif 25 microgram HCV core pcDNA3+CpG motif 50 microgram HCV core pcDNA3+CpG motif 10 microgram HCV core pcDNA3+CpG motif+Alum 25 microgram HCV core pcDNA3+CpG mitif+Alum 50 microgram HCV core pcDNA3+CpG motif+Alum 10 microgram HCV core pcDNA3+Dendrosome 25 microgram HCV core pcDNA3+Dendrosome 1 17 42 62 Table Immunization of HCV core pcDNA3 with four different adjuvants Figure 1. The dose (left) and duration (right) of interferon-α in relation to the HBeAg clearance (log scale). Y-axis means the log scale of HBeAg clearance, X-axis means the dose of interferon-α. Each trial is represented by a circle, the area of which represents the trial’s precision. Larger circles represent trial that contribute more information. Regression equation: log OR(HBeAg clearance) = 0.34 + 0.156 × dose, and log OR (HBeAg clearance) = −0.51 + 0.076 × duration